DEF 14A: Celularity Inc. Announces 2024 Annual Meeting of Stockholders

Celularity Inc. will hold its 2024 Annual Meeting of Stockholders on December 19, 2024, to elect a Class III director and ratify the appointment of its independent auditor.

Summary

• Celularity Inc. is holding its 2024 Annual Meeting of Stockholders on December 19, 2024, at 1:00 p.m. Eastern Time at its headquarters in Florham Park, New Jersey.
• The primary purpose of the meeting is to elect Robert J. Hariri, M.D., Ph.D., as the Class III director for a term expiring in 2027.
• Stockholders will also vote to ratify the appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for determining stockholders eligible to vote is November 8, 2024.
• As of the record date, there were 22,005,358 shares of Class A common stock outstanding, each entitled to one vote.
• The board of directors recommends voting for the election of the director nominee and in favor of the ratification of the accounting firm appointment.
• Stockholders can vote by telephone, internet, mail, or in person at the meeting.
• The company's board of directors consists of six members, divided into three classes with staggered three-year terms.
• The board has determined that all members except Dr. Hariri are independent directors.
• The company has established an audit committee, a compensation committee, and a nominating and corporate governance committee.

Sentiment

Score: 6

Explanation: The document is largely procedural and factual, with some concerns about related-party transactions and financial stability. The sentiment is neutral to slightly positive.

Positives

• The company has a clear process for electing directors and ratifying the appointment of its independent auditor.
• The board of directors is largely composed of independent members, which is good for corporate governance.
• The company has established key committees to oversee audit, compensation, and corporate governance matters.
• The company has a clawback policy in place to recover incentive compensation in case of accounting restatements.
• The company provides multiple ways for stockholders to vote, including by telephone, internet, mail, and in person.

Negatives

• The company's CEO, Dr. Hariri, is not considered an independent director.
• The company incurred significant audit fees of $2,139,760 from Deloitte & Touche LLP in 2023.
• The company has had some late filings of Section 16(a) reports by directors and officers.
• The company has a number of related party transactions, including loans and consulting agreements.

Risks

• The company's dependence on related-party financing could pose a risk if those relationships change.
• The company's minimum liquidity covenant was breached in 2023, which could indicate financial instability.
• The company has a complex capital structure with various warrants and convertible notes, which could dilute existing shareholders.
• The company's clawback policy could lead to disputes if there are accounting restatements.
• The company's reliance on a single individual, Dr. Hariri, as both CEO and Chairman could pose a risk if he were to leave the company.

Future Outlook

The company intends to continue to leverage the broad expertise of its scientific advisors and to comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC and Nasdaq rules and regulations.

Management Comments

• The board of directors believes that combining the positions of Chief Executive Officer and Board Chair helps to ensure that the board of directors and management act with a common purpose.
• The board of directors believes that a combined Chief Executive Officer/Board Chair is better positioned to act as a bridge between management and the board of directors, facilitating the regular flow of information.

Industry Context

This announcement is typical for a publicly traded company, outlining the agenda for its annual meeting and providing information to shareholders. The focus on corporate governance and financial oversight is consistent with industry best practices.

Comparison to Industry Standards

• The board composition, with a majority of independent directors, aligns with Nasdaq listing requirements and is a common practice among publicly traded companies.
• The establishment of audit, compensation, and nominating committees is standard for companies of this size and complexity.
• The disclosure of related-party transactions is also a common practice, although the number and value of such transactions may be higher than some peers.
• The executive compensation structure, including base salary, bonus, and equity awards, is typical for companies in the biotechnology sector.
• The company's clawback policy is in line with regulatory requirements and industry best practices for corporate governance.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into various loan agreements with related parties, including Dr. Robert Hariri, C.V. Starr & Co., Inc., and Resorts World Inc Pte Ltd.
• The company has amended and restated warrants with Starr International.
• The company has entered into a securities purchase agreement with Dr. Robert Hariri.
• The company has a license agreement with Celgene Corporation.
• The company has consulting agreements with Dr. Pecora and Robin L. Smith M.D.
• Alexandra Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., is employed by the company.
• The company has indemnification agreements with its directors and executive officers.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key matters at the Annual Meeting.
• Employees are affected by the company's compensation and benefit policies.
• The company's financial performance and strategic decisions impact its creditors and suppliers.
• The company's related-party transactions may raise concerns for some stakeholders.
• The company's clawback policy could impact executive compensation.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting.
• Final voting results will be published in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Independent Auditor, Corporate Governance, Audit Committee, Compensation Committee, Stockholders, Related Party Transactions, Executive Compensation, Financial Reporting